key: cord-0998243-p0r0g35h
authors: Aleebrahim-Dehkordi, Elahe; Soveyzi, Faezeh; Deravi, Niloofar; Rabbani, Zahra; Saghazadeh, Amene; Rezaei, Nima
title: Human coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 in children
date: 2020-10-22
journal: J Pediatr Nurs
DOI: 10.1016/j.pedn.2020.10.020
sha: f72ee7cb10a5200e5d15d5d68dd509cc503c2231
doc_id: 998243
cord_uid: p0r0g35h

The novel coronavirus, known as 2019-nCoV or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused an epidemic with high mortality and morbidity since December 2019, in Wuhan, China. The infection has now been transmitted to more than 210 countries worldwide and caused more than 200,000 deaths. Similar to other coronaviruses such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS-CoV-2 appears to less commonly affect pediatrics and to cause less severe disease along with fewer symptoms compared to adults. Available data suggest that the pediatric population is just as likely as adults to become infected with SARS-CoV-2. However, they may be asymptotic or have milder symptoms than adults; they can be potential carriers of the disease. This article reviews the present understanding of SARS-CoV-2 infection in the pediatric age group in comparison with MERS-CoV and SARS-CoV.

In the last two decades, the world has faced three epidemics caused by coronaviruses, resulting in significant global health concerns (18) .

In 2002-2003, SARS-CoV emerged in Guangdong, China. It spread rapidly to other areas and countries, including Hong Kong, China's particular administrative area, Singapore, Vietnam, and Canada (19) . After having infected more than 8,000 people and resulting in 774 deaths with a mortality rate calculated at 9.5%, the latest patient diagnosed with SARS-CoV occurred in September 2003 (18) . The first pediatric patients with SARS-CoV were hospital staff contacts (20) .

Stockman et al. (21) . state that of the 135 pediatric cases with SARS documented in the six publications, 80 had laboratory-confirmed SARS, and 27 existed in the SARS-affected regions (3%).

There was no known source of SARS in less than two percent of pediatric patients. indicates that each patient with MERS-CoV transfers the disease to one other individual only, models estimate an R0 of 4 for SARS-CoV that corresponds to relatively higher transmissibility of this virus (18, 22) . However, as compared to SARS-CoV, MERS-CoV is more deadly, with the death rate of about 35%.

In December 2019, the novel coronavirus disease was recognized in Wuhan, China, in some patients with an unknown form of viral pneumonia, along with a common history of being in the Huanan seafood market (24) . By March 22, the new coronavirus pandemic has been spread to over 185 countries from China and appears not to be more fatal than other similar viruses, such as MERS and SARS (25, 26) . The director-general of the WHO, Tedros Adhanom Ghebreyesus, at a meeting on February 17, stated that over 80% of cases with COVID-19

have "mild disease and will recover", and in 2% of reported patients, it appears to be fatal (27) .

Although the case fatality rate is lower in COVID-19 infected individuals, COVID-19 has resulted in about 3 million confirmed cases as well as more than 200,000 deaths by April 26, 2020 . It forms a contrast with SARS and MERS that were totally accounted for less than 2000 deaths (1632). During the pandemic of COVID-19, the older population, people with comorbid conditions, such as cardiovascular diseases and cancer, and individuals with a certain genetic background appear as the most vulnerable populations (28) (29) (30) (31) . In the early stages of the COVID-19 epidemic, pediatric SARS-CoV-2 infected individuals appeared infrequent. Therefore, the pediatric age group is not yet considered at high risk of this disease. However, the pediatric population infected by SARS-CoV-2 was gradually increased in line with the increase of familial clusters (26, 32) . By February 11, 2020, the Chinese Centers for Diseases Control and Prevention has reported 44672 confirmed SARS-CoV-2 infected cases, 549 cases (1.2%) of whom were 10-19 years old and 416 cases (0.9%) of whom were 0-10 years old. Of these infected children, 134 cases had clinical records (33). There have been two reported deaths in the pediatric age group, who tested positive for SARS-CoV-2 infection in China; however, no deaths have been reported in the published papers from other countries (34) . Furthermore, a cohort of 31 patients (under  shown clinical manifestations, including cough, chills, fatigue, vomiting, diarrhea, rhinorrhea,   diarrhea, and respiratory distress, and laboratory abnormalities, including leukopenia, elevated AST, elevated AST, and lymphopenia. Laboratory results such as thrombocytopenia, lymphopenia, and elevation in CPK and liver transaminase levels appeared mild in young children. Results suggest that SARS is a relatively mild and nonspecific respiratory illness in young children. The clinical features observed in teenagers resemble those of adults (37, 38) .

MERS-CoV can cause a wide range of symptoms from mild fever and respiratory symptoms (upper respiratory tract infection), diarrhea, weakness, and lethargy, to progressive respiratory failure, renal failure, or multiple organ failure in severe cases. The most common manifestations of the disease are fever and respiratory symptoms, and all patients develop respiratory symptoms during their illness (22, 23) . Cases of anemia, coagulopathy, and intravascular coagulation have also been reported in patients with MERS-CoV. There have also been reports of increased levels of serum transaminases, lactate dehydrogenase, potassium, creatine kinase, troponin, C-reactive (CRP) protein, and procalcitonin, and decreased serum sodium and albumin levels (39, 40) . The MERS-CoV virus produces symptoms similar to SARS, but with a distinct clinical course and high mortality rates of between 35-50%. The rate of death from MERS is higher in men as well as in patients with underlying diseases. The average time from the onset of symptoms to hospitalization is approximately four days, and the average time from admission to hospital to admission to the ICU is one day. The ICU admission period is approximately 30 days. However, death occurs, on average, 12 days after the onset of symptoms (41) (42) (43) .

J o u r n a l P r e -p r o o f Furthermore, out of 701 patients with confirmed MERS-CoV, only 14 were pediatric cases (2%).

Compared to adult patients, MERS-CoV in children is less frequent and seems to be associated with less mortality unless the patient has an underlying disease or a history of infection with other respiratory viruses. Based on the results of the screening, it has been found that one of the children (9-month-old child) with MERS-CoV disease has nephrotic syndrome. Different results show that although few cases of MERS-CoV in children have been reported, MERS remains mainly a disease of adults.

According to the first study of patients with new coronavirus (SARS-CoV-2), the incubation period of the virus was, on average, five days, with a range between 4 and 7 days (44) . According to the present epidemiological evidence, the incubation period of COVID-19 infections varies from 1 to 14 days, generally ranging from 3 to 7 days. SARS-CoV-2 tends to locate and replicate in the cells of the lower respiratory tract (45) . At the initial stage of infection with SARS-CoV-2, people have general nonspecific symptoms such as fatigue, body aches, fever, dry cough, nausea, and diarrhea. Also, patients may develop neurological manifestations, such as headach and anosmia (46) (47) (48) (49) .

Infected children might appear asymptomatic or present with a dry cough, fever, and fatigue, and gastrointestinal symptoms such as diarrhea, abdominal discomfort, nausea, and vomiting. At the disease onset, some cases show fever, cough, and fatigue that is accompanied by nasal congestion, expectoration, runny nose, headache, and diarrhea. The majority of children have a low-grade fever or no fever at all (21) . As the condition progresses, dyspnea, cyanosis, and other signs may arise after typically one week of the disease, along with systemic toxic signs, including restlessness or malaise, decreased appetite, poor feeding, and less activity. Children's condition might progress quickly and turn to respiratory failure, which cannot be improved by conventional oxygen (nasal catheter, mask) within 1-3 days. Metabolic acidosis, septic shock, irreversible bleeding, and coagulation dysfunction can take place in such severe cases (54). Xia et al. (55) reported that 7 of 20 pediatric cases had a history of acquired or congenital diseases, indicating that children with underlying diseases can be more vulnerable to COVID-19. Pediatric patients usually have a better prognosis, with an average stay of 12.9 days in the hospital. As for adults, COVID-19 can rapidly spread in children. However, it is more likely to remain asymptomatic in children than adults (56) .

Unlike adults, most children with COVID-19 have mild symptoms. However, COVID-19 may cause an inflammatory reaction in some children (57, 58) . In late April 2020, a group of children was admitted to the intensive care unit for a multi-system inflammatory disease. It appeared that the disease could be related to COVID-19. Also, there were eight children from England, in whom excessive hyperinflammatory shock was observed (57) and COVID-19 related antibodies were present as well (59) . The so-called multi-system inflammatory syndrome in children (MIS-C) is very similar to a type of childhood disease known as Kawasaki disease. Kawasaki disease causes inflammation in the blood vessel walls (60, 61). Coronary artery aneurysm is a major complication of Kawasaki disease. The diagnosis is based on the persistent presence of symptoms such as eczema, lymphadenopathy, fever, conjunctival injection, and changes in the mucous membranes and organs (62, 63) . Examination of the clinical and laboratory characteristics of MIS-C shows that the syndrome is distinct from Kawasaki's disease. Children with MIS-C are older and systemic inflammation is more severe in them, and they have more myocardial damage than patients with Kawasaki's disease (64) . Children with MIS-C show both the symptoms of COVID-19 and toxic shock syndrome (TSS) and Kawasaki disease (60, 65). MIS-C can affect different parts of the including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal tract.

Children with MIS-C mostly have abdominal pain or sometimes diarrhea, neck pain, rash, bloodshot eyes, and vomiting. They may also experience excessive fatigue (66, 67) . Cases of MIS-C have been reported in several countries (68) (69) (70) . This syndrome appears to occur two to four weeks after infection with COVID-19. In countries where the prevalence of COVID-19 is high, more cases of MIS-C have been reported in children (57, 71) . Children with this syndrome might J o u r n a l P r e -p r o o f suffer from heart problems and need immediate care (72) . It is not yet fully understood what causes MIS-C (57).

Coronaviruses (CoVs) are a family of enveloped RNA viruses (42) that display crown-like spikes on their surfaces (73) (74) (75) . In particular, SARS-CoV-2 possesses a typical RNA that encodes 27 proteins. The orf1ab and orf1a genes, which are located at the 5' end of the genome, encode the pp1ab and pp1a proteins, respectively. Together, these two genes express 15 nonstructural proteins nsp1-nsp10 and nsp12-nsp16. On the other hand, at the 3' end of the genome, four structural proteins, including the spike surface protein (S), an envelope protein (E), membrane protein (M), nucleocapsid protein (E), and eight subunit proteins, including 3a, 3b, p6, 7a, 7b, 8b, 9b, and orf 14 are coded (76, 77) .

Although coronaviruses are more common in animals, seven of them can affect humans (83) . Therefore, presently, the probable transmission routes (i.e., airborne vs. contact) for SARS-CoV-2 is a highly debated topic among the research communities worldwide (88) .

It might also be possible for SARS-CoV-2 to be transmitted via the oral-fecal route as well. Supporting this, the fecal samples of some patients with COVID-19 were positive for the viral nucleic acid. However, the accuracy of this pattern of transmission needs more investigation (81) .

There is documented data about the vertical transmission of SARS-CoV and MERS-CoV (78, 81) .

A mother with SARS-CoV is at increased risk for complications such as spontaneous miscarriage, intrauterine growth retardation, preterm labor, and coagulopathy problems (78, 91) . The data from six newborns born from mothers with COVID-19 showed that samples from amniotic fluid and the umbilical cord lacked SARS-CoV-2 RNA. Also, the neonatal pharynx sample and mother breastmilk were negative for the nuclear acid of COVID-19 (81) . The results of another study in china on nine mothers who had COVID-19 associated pneumonia were similar to the previous one, and there was no virus detected in all samples. The Apgar score of nine neonates was high, and there were no signs of asphyxia in them (91) . The current evidence is not enough to conclude that SARS-CoV-2 can be transmitted from an infected mother to her fetus (81, 92, 93) .

Because the perinatal transmission is suspicious, pregnant women who have a history of travel to affected areas or have a history of exposure to infected patients are recommended to be tested for COVID-19, even if they are asymptomatic (92) .

The outbreak of SARS-CoV is related to wildlife (94) . The source of MERS-CoV infections may be related to camels. The origin of the novel coronavirus is not completely clear, but a zoonotic J o u r n a l P r e -p r o o f origin of the disease is well-documented. The first confirmed cases of COVID-19 were related to markets that sell seafood, the meat of wild animals (94) , snakes, and other animals like livestock animals and live rabbits too. Furthermore, high similarities between the SARS-CoV-2 and bat coronaviruses support the bat origin of SARS-CoV-2 (80).

First of all, the history of exposure to infected patients or travel to the affected areas and laboratory data such as procalcitonin (PCT), complete blood count, and C-reactive protein can help us to diagnose this infection (81, 95) . A very advantageous instrument for distinguishing SARS infected children from the others is real-time reverse transcription-polymerase chain reaction (RT-PCR). RT-PCR is also used for MERS-CoV nucleic acid detection, too (82) . It takes a few hours for the test to count the RNA viruses in the serum (78) . However, the value of conventional RT-PCR decreases along the first week of the SARS-COV infection (78) , and its sensitivity is not acceptable. In a study of pediatric cases with SARS, conventional RT-PCR of fecal and nasopharyngeal specimens could detect less than 50% of real patients (78) . Laboratory findings of SARS-COV in children include increased lactate dehydrogenase (LDH), decreased neutrophil count, and elevated creatinine phosphokinase (CPK) (78) . Incomplete airspace filling at the edge of the lung indicates the SARS-CoV infection.

Nowadays, the nucleic acid test is the gold standard for the diagnosis of COVID-19 (81, 95) .

Among the specimens taken for the diagnosis of COVID-19, the most convenient one is nasopharyngeal swab, with the sensitivity rate close to 50% and less (81) . Lower respiratory tract secretions such as bronchoalveolar lavage fluid that contains a high amount of viral RNA are more valid specimens for the detection of the novel coronavirus (79, 81) . Also, the pharyngeal J o u r n a l P r e -p r o o f swab was used one day after labor for an asymptomatic newborn infected with COVID-19 (95) .

spread the virus among other people, so the test should be repeated for them (95) . Imaging data could help us with the diagnosis of COVID-19 in children. High resolution computed tomography (HRCT) can be more helpful than a chest X-ray in this regard. Imaging abnormalities related to COVID-19 include ground-glass opacities (GGO) and peribronchial thickening (78) . Previously it was thought that among children with COVID-19, female ones are affected more than male ones. However, recent reports show the reverse, raising the need to further surveys to investigate the issue. The manifestations of COVID-19 vary from asymptomatic, mild, and moderate to severe and critical ones. Some of the underlying conditions like malnutrition, congenital heart disease, and hydronephrosis might make children susceptible to severe COVID-19.

Moreover, children may develop respiratory coinfections like mycoplasma pneumonia, influen-J o u r n a l P r e -p r o o f za virus, Epstein-Barr virus, respiratory syncytial virus, parainfluenza virus, and adenovirus (103) (104) (105) (106) (107) .

Possible sources of infection in children affected by COVID-19 include contact with infected adults (with the history of travel to endemic areas or contact with a person living in such areas), having at least one family member infected with COVID-19, presence in population clusters, living in or traveling to affected areas, having visited a hospital or a history of contact with animals (106, (108) (109) (110) (111) . Vertical transmission from infected mothers needs further investigations to be clarified as a predisposing factor (103, (112) (113) (114) .

In a case-control study in five hospitals in Hong Kong, Seto et al. revealed that the use of masks could markedly reduce the risk of SARS-CoV infection among healthcare workers. Among surveyed noninfected staff members who wore masks, 15.3% of them were reported to have used paper masks, 30.7% surgical masks, and 54.4%, N95 masks. Contact and droplet precautions alone were shown to be sufficient to protect against SARS-CoV infection. Additionally, no marked difference was revealed between the surgical and N95 masks (115) . In its May 2003 interim Domestic Guidance on the use of respirators to prevent transmission of SARS, the US Centers for Disease Control and Prevention (CDC) reported that disposable N95 respirators are sufficient for routine airborne isolation precautions. However, in case N95 masks were not available, a surgical mask should be worn (116) . Regarding SARS, children with mild symptoms and patients with the common flu-like manifestations of the disease at the initial phase could transmit the infection, which demanded early detection and separation of these children (109, 117) . Also, suspension of schools, contact tracing, preparing wards with negative pressure ven-J o u r n a l P r e -p r o o f tilation for the infected patients, and practicing hygiene preventions by schools were recommended (118, 119) .

Additionally, WHO supported the use of surgical (procedure) masks when caring for suspects with either possible or confirmed MERS-CoV infection as well as particulate respirators in case of aerosol-generating procedures (120) . CDC also supported the use of particulate respirators additional to airborne precautions for all MERS patient care activities (121) . For MERS prevention, besides points stated for SARS, cooking or pasteurization of camel products and avoidance of contact with camels and their products, touching nose, eyes, and mouth while working with camels were considered (122) (123) (124) .

COVID-19 has now turned into an endemic matter, which is spreading rapidly. In order to break this cascade of distribution, some preventive measures are needed both in society and healthcare levels. Some of the precautions needed to be considered by the healthcare system include early identification and isolation of the infected patients in wards with appropriate environmental ventilation, isolation of the neonates born from infected mothers and examining them for COVID-19, training the health care personnel to use adequate personal protective equipment, and optimization of medical intervention and personnel visiting in order to reduce nosocomial transmission. Besides, carrying patients with special vehicles and by fully protected staffs, standard elimination of the dischargeable productions of the patients, and isolation of the infants with the underlying disease early after delivery is necessary to be considered. strong parental work as well as school lessons on this issue, child cooperation is obtained, and thus, the use of masks in children is preceded (129) . However, protecting healthy children with mask faces difficulties. Children younger than two years of age are recommended not to wear any type of masks since their very small airways might then struggle to breathe. Furthermore, since without assistance, they may be unable to remove the masks, they can be at high risk of suffocation (130) . Surgical masks suitable for children from 3 to 12 years old are now widely marketed, and they can also be prepared at home from commonly available materials at low cost, according to the US Centers for Disease Prevention and Control (130) .

During the process of delivery in the infected mothers, merely essential staff with appropriate personal protective equipment should be present, and the mother has to wear masks and maintain hand hygiene. The resuscitation personnel should keep a distance of at least 2 meters between the newborn and the mother. After the delivery, the mother should be encouraged to J o u r n a l P r e -p r o o f Journal Pre-proof breastfeeding while wearing a mask (131) . Tele triaging patients and quarantines are important strategies to be provided by the health care system (132) . People should be educated to practice appropriate interpersonal distance and to restrain themselves from touching their eyes and mouth with unwashed hands (133, 134) .

There is no specific antiviral drug to treat COVID-19, SARS, and MERS. The primary treatment of these conditions involves the correction of electrolyte and acid-base imbalance and oxygenation. In this context, there are no adequate clinical trials in pediatric cases. The treatment protocols for children are, therefore, similar to those for adults (81) .

Studies recommend a combination of drug therapy for patients with MERS infection. This combination therapy consists of a nucleoside inhibitor named Ribavirin and subcutaneous interferons (IFNs) such as IFNα-2b and IFNβ. It could decrease pulmonary damage and boost the 14-day survival but failed to improve 28-day survival (79, 82) . Broad-spectrum antibiotics were considered for children with SARS who had symptoms of fever and pneumonia. In phase 2 of SARS infection, systemic corticosteroids might be administrated to regulate the immune system and reduce lung damage. Intravenous methylprednisolone pulse therapy was associated with better clinical and radiological outcomes in children with severe SARS infection (78) .

Corticosteroid therapy is also used in patients with severe COVID-19 (135, 136) , even though the incorrect use of broad-spectrum antibiotics and corticosteroids could increase the mortality rate in adults with COVID-19. However, patients with severe COVID-19 disease might develop hyper inflammation and a cytokine storm (137) (138) (139) (140) (141) . Interestingly, COVID-19 seems to happen and become severe in people with primary immune deficiency disorders less than in the general J o u r n a l P r e -p r o o f Journal Pre-proof population (142, 143) . This suggests the role of the immune system in contributing to COVID-19 (138) and therefore indicates the diagnosis and treatment of hyperinflammatory state as crucial for reducing mortality. Hence for this subgroup, immunosuppression using corticosteroids, Janus kinase (JAK) inhibitors, selective cytokine blockade, and intravenous immunoglobulin can be considered (81, (144) (145) (146) (147) (148) .

Moreover, a recent study investigated the role of extracorporeal membrane oxygenation (ECMO) in the management of severely ill individuals with confirmed COVID-19 who develop acute respiratory and cardiac compromise refractory to conventional therapies. This analysis of 32 COVID-19 patients with severe pulmonary compromise supported with ECMO stated that ECMO could be useful in salvaging critically ill participants with COVID-19. However, further studies are necessary to enhance our understanding of the role of ECMO in patients with COVID-19 and ARDS (149) .

Except in critical cases, children with COVID-19 did not require antiviral drug treatment because they could be recovered on their own (95) . The administration of Remdesivir seems to have positive effects (150) , but its efficacy has not been proven for children.

In the early stages of COVID-19, it was thought that children were rarely affected by the virus (151) . However, current reports suggest that children are just as affected as adults but with milder symptoms, lower disease severity, and lower mortality (152, 153) . SARS-CoV-2 is transmitted through human-to-human contact and occurs within both family and social relationships (154) . It is difficult for children, especially toddlers, to follow the principles of hygiene, and baby J o u r n a l P r e -p r o o f carriers are expected to transmit the COVID-19. The lack of awareness of the disease in affected children is another possible explanation for the high rate of disease transmission (155) . Children are likely to expose themselves to other children, friends, and family members, and this directly correlates with the person to person transmission of COVID-19 (156) .

There are many limitations to the PCR method, such as high rates of people with false-negative tests. It also takes a long time for the PCR test to tell us the result, so rapid tests are needed to prevent the spread of the coronavirus from suspect cases to the general population (157) .

Serological testing based on antibodies can be used for patients with asymptomatic infection.

Recently studies reported the development of rapid antibody tests with the use of nucleocapsid and spike proteins as antigens. These tests work based on the detection of both IgG and IgM antibodies in whole blood or serum samples simultaneously. They might take about 15 minutes and have reasonable specificity and sensitivity (158) (159) (160) .

6.7% of children get the infection severely, and the rest is known as asymptomatic carriers. It is, therefore, essential to identify asymptomatic or mild infected children to prevent the virus from spreading (161) . Based on the current evidence, viral load in symptomatic cases and asymptomatic carriers is approximately the same. The late identification of asymptomatic carriers makes them a source of uncontrollable infection (162) . As a result, paying attention to children who get the infection less severe than adults and identifying early asymptomatic ones will help prevent the transmission of the virus (163).

According to the recommendations of the WHO, it is better not to separate children from their families during this pandemic and ask children to speak about their emotions to give them a sense of calm. There are simple but effective ways to entertain children, such as painting or playing with them. Depending on the age of the children, it is appropriate to provide them with useful disease-related information to the extent of their understanding because they will become more curious during the crisis and ask more questions of their parents (164) . According to the behavioral research conducted on children aged between 3 to 18 in Shaanxi, clinginess is the most prevalent problem, especially in younger children (3-6 years old). Since children in epidemic areas suffer from fear, using media as a hobby could help them to forget about their bad feelings (165) .

In the past two decades, the world has witnessed three outbreaks caused by coronaviruses: SARS-CoV, MERS-CoV, and SARS-CoV-2. Studies propose a zoonotic origin for these three coronaviruses. These pathogens can affect pediatrics as well as adults. However, the majority of the children show mild manifestations except for the ones with underlying conditions. Among pediatrics, the main signs and symptoms include fever, respiratory symptoms, and other flu-like manifestations. Nucleic acid tests and imaging techniques are used for the diagnosis. Serological tests have reasonable specificity and sensitivity and can also be used for diagnosis of a new infection, recent infection, and re-infection as well (166) . Public education for practicing hygiene and contact avoidance with infected patients, as well as isolation of the contaminated people, should be taken into consideration. As no precise drug treatment has been discovered J o u r n a l P r e -p r o o f up to date, supportive and symptom alleviating treatments are the principal therapies. However, regenerative medicine and targeted therapies pose potentials to the COVID-19 (51, 146, 147, (167) (168) (169) (170) . The potentials need testing at large, and this would be well-achieved when all collaborate (171) (172) (173) (174) (175) .

The authors declare that they have no competing interests

There is no funding for the present study Authors' contributions E.A.D., F.S., N.D., and Z.R. conceptualized the study and prepared the initial draft. A.S. prepared the final draft. N.R. supervised the project and critically appraised the manuscript.

Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

Characterization of a coronavirus isolated from a diarrheic foal

A Novel Coronavirus from Patients with Pneumonia in China

Molecular epidemiology, evolution and phylogeny of SARS coronavirus

Histopathology of Middle East respiratory syndrome coronovirus (MERS-CoV) infection -clinicopathological and ultrastructural study

A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Travel medicine and infectious disease

MERS-coronavirus: From discovery to intervention. One health

Transmission of MERS-coronavirus in household contacts

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan

COVID-19: Developing from an Outbreak to A Pandemic. Archives of medical research

SARS-CoV-2: A comprehensive review from pathogenicity of the virus to clinical consequences

Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement

COVID-19 affects healthy pediatricians more than pediatric patients

Three Emerging Coronaviruses in Two Decades: The Story of SARS, MERS, and Now COVID-19

Epidemiological and Clinical Characteristics of SARS-CoV-2 and SARS-CoV: A System Review. Available at SSRN 3541144

Severe acute respiratory syndrome (SARS) in neonates and children

Severe acute respiratory syndrome in children. The Pediatric infectious disease journal

Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-ncov infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections

Middle East Respiratory Syndrome Coronavirus and Children: What Pediatric Health Care Professionals Need to Know

The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? International journal of epidemiology

The proximal origin of SARS-CoV-2. Nature medicine

COVID-19, Diabetes Mellitus and ACE2: The conundrum. Diabetes research and clinical practice

Coronavirus: covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate

Cardiovascular diseases burden in COVID-19: Systematic review and meta-analysis

Colon cancer and SARS-CoV-2: impact of ACE2 expression in susceptibility to

Death due to COVID-19 in Three Brothers. The American journal of tropical medicine and hygiene

Genetic predisposition models to COVID-19 infection

Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults

COVID-19 infection in children. The Lancet Respiratory Medicine

Coronavirus Disease-19 Among Children outside Wuhan

SARS transmission among hospital workers in Hong Kong

Clinical picture, diagnosis, treatment and outcome of severe acute respiratory syndrome (SARS) in children

Children hospitalized with severe acute respiratory syndrome-related illness in Toronto

CT correlation with outcomes in 15 patients with acute Middle East respiratory syndrome coronavirus

Health Care Associated Middle East Respiratory Syndrome (MERS): A Case from Iran

Middle East Respiratory Syndrome Coronavirus (MERS-CoV) origin and animal reservoir

Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus

Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. The Lancet Infectious diseases

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

COVID-19: what is next for public health?

COVID-19): A Perspective from China

Anosmia: a missing link in the neuroimmunology of coronavirus disease 2019 (COVID-19). Reviews in the neurosciences

Central Nervous System Involvement in COVID-19. Archives of medical research

The involvement of the central nervous system in patients with COVID-19

Coronavirus Infections in Children Including COVID-19 -An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children. The Pediatric infectious disease journal

Lymphopenia in COVID-19: Therapeutic opportunities

Sex differences in clinical findings among patients with coronavirus disease 2019 (COVID-19) and severe condition. medRxiv

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges

Severe acute respiratory syndrome

Serial analysis of the plasma concentration of SARS coronavirus RNA in pediatric patients with severe acute respiratory syndrome

First case of neonate infected with novel coronavirus pneumonia in China. Zhonghua er ke za zhi= Chinese journal of pediatrics

Hyperinflammatory shock in children during COVID-19 pandemic. The Lancet

Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2: A Systematic Review. The Journal of Pediatrics. 2020. 60. Prevention CfDCa. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. The Lancet

Dissecting Kawasaki disease: a state-of-the-art review

Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association

Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. Jama. 2020. 65. (PICS) PICS. PICS Statement: Increased number of reported cases of novel presentation of multi-system inflammatory disease

Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study

Multisystem inflammatory syndrome in children and adolescents with COVID

World Health Organization

Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents

Hyperinflammatory shock related to COVID-19 in a patient presenting with multisystem inflammatory syndrome in children: First case from Iran

Rapid risk assessment: pediatric inflammatory multisystem syndrome and SARS -CoV-2 infection in children. European Centre for Disease Prevention and Control

Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic

Preliminary epidemiologic assessment of MERS-CoV outbreak in South Korea

Severe respiratory illness caused by a novel coronavirus

A novel coronavirus associated with severe acute respiratory syndrome

Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell host & microbe

The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies

Severe acute respiratory syndrome (SARS) in neonates and children. Archives of disease in childhood Fetal and neonatal edition

Middle East respiratory syndrome

Another Decade, Another Coronavirus

Monoclonal antibody as a potential anti-COVID-19

Emerging Respiratory Viruses in Children

Identifying airborne transmission as the dominant route for the spread of COVID-19

):e146. 86. (CDC) CfDCaP. Coronavirus disease 2019 (COVID-19) -social distancing, quarantine, and isolation

It is time to address airborne transmission of COVID-19

Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals

Reducing transmission of SARS-CoV-2. Science

A Controversial Debate: Vertical Transmission of COVID-19 in Pregnancy

Guidelines for pregnant women with suspected SARS-CoV-2 infection. The Lancet Infectious Diseases

The impact of COVID-19 on pregnancy and neonatal health: a systematic review

A strategy to prevent future epidemics similar to the 2019-nCoV outbreak. Biosafety and Health

Corona Virus Disease 2019, a growing threat to children

Childhood severe acute respiratory syndrome in Taiwan and how to differentiate it from childhood influenza infection. Archives of pediatrics & adolescent medicine

Clinical presentations and outcome of severe acute respiratory syndrome in children

Middle East respiratory syndrome in children. Dental considerations. Saudi medical journal

Middle East respiratory syndrome coronavirus in children

Middle East respiratory syndrome coronavirus disease in children. The Pediatric infectious disease journal

Middle East Respiratory Syndrome Coronavirus and Children

SARS in newborns and children

Coronavirus disease (COVID-19) and neonate: What neonatologist need to know

COVID-19 in Singapore-Current Experience: Critical Global Issues That Require Attention and Action

Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue

Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. Pediatric pulmonology

A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features

Corona Virus Disease 2019, a growing threat to children?

Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures

Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records

Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia

Coronavirus Disease 2019 (COVID-19) During Pregnancy: A Case Series

Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS)

Interim Domestic Guidance on the Use of Respirators to Prevent Transmission of SARS 6

Characteristics of COVID-19 infection in Beijing

Severe acute respiratory syndrome (SARS) in children: epidemiology, presentation and management

Severe acute respiratory syndrome (SARS) in neonates and children. Archives of disease in childhood Fetal and neonatal edition

Infection prevention and control during health care for probable or confirmed cases of novel coronavirus (nCoV) infection: interim guidance

Interim Infection Prevention and Control Recommendations for Hospitalised Patients with Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Middle East respiratory syndrome

An update on Middle East respiratory syndrome: 2 years later

Disease-a-month : DM

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Novel coronavirus infection in hospitalized infants under 1 year of age in China

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

COVID-19: A Chimera of Two Pandemics. Disaster medicine and public health preparedness

To mask or not to mask children to overcome COVID-19

Use of cloth face coverings to help slow the spread of COVID-19

Coronavirus Disease 2019 (COVID-19) in Children -What We Know So Far and What We Do Not

COVID-19 and telemedicine: Immediate action required for maintaining healthcare providers well-being

Coronavirus Disease (COVID-19) With Relevance to Pediatrics

Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review

The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? International journal of epidemiology

Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids

Cytokines and COVID-19: friends or foes?

The immune system and COVID-19: Friend or foe? Life sciences

Immune-epidemiological parameters of the novel coronavirus -a perspective

SARS-CoV-2-A Tough Opponent for the Immune System. Archives of medical research

Hyperinflammatory shock related to COVID-19 in a patient presenting with multisystem inflammatory syndrome in children: First case from Iran

COVID-19 in a Child with Primary Specific Antibody Deficiency

Primary Immunodeficiency Diseases in COVID-19 Pandemic: A Predisposing or Protective Factor? The American journal of the medical sciences

Immunosuppression for hyperinflammation in COVID-19: a doubleedged sword?

COVID-19: consider cytokine storm syndromes and immunosuppression

The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19

Immunotherapy for SARS-CoV-2: potential opportunities

Efficacy of Plasmapheresis and Immunoglobulin Replacement Therapy (IVIG) on Patients with COVID-19

Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in Coronavirus Disease 2019: Experience with 32 Patients

Computational drug discovery and repurposing for the treatment of Covid-19: A systematic review. Available at SSRN 3583748

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children. The Pediatric infectious disease journal

Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts

COVID-19: Transmission, prevention, and potential therapeutic opportunities

Perinatal Transmission of COVID-19 Associated SARS-CoV-2: Should We Worry? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. The New England journal of medicine

Microfluidic devices for detection of RNA viruses

Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis

Antibody responses to SARS-CoV-2 in patients with COVID-19

An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment

Novel coronavirus disease (COVID-19) in children. Turkish journal of medical sciences

COVID-19 transmission through asymptomatic carriers is a challenge to containment. Influenza and Other Respiratory Viruses

COVID-19 in Children: An Ample Review

WHO. Mental health and psychosocial considerations during the COVID-19 outbreak WHO

Behavioral and Emotional Disorders in Children during the COVID-19 Epidemic

With Risk of Reinfection, Is COVID-19 Here to Stay? Disaster medicine and public health preparedness

COVID-19 and Medical Biotechnology

COVID-19 and picotechnology: Potential opportunities

Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises

Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting

All together to Fight COVID-19. The American journal of tropical medicine and hygiene

Borderless collaboration is needed for COVID-19-A disease that knows no borders

The urgent need for integrated science to fight COVID-19 pandemic and beyond

Quantity does not equal quality: scientific principles cannot be sacrificed

COVID-19 in Iran: A Deeper Look Into The Future. medRxiv

Not applicable